Search results for "Psychotic"

showing 10 items of 360 documents

Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study

2011

Preventing relapse during the first years of illness has a critical impact on lifelong outcomes in schizophrenia. A better understanding and improvement in factors which influence relapse should diminish the risk of relapse and consequently improve the outcome of the illness.To identify factors associated with relapse after 3 years of a first episode in a sample of non-affective psychosis patients who are representative of clinical practice in an epidemiological catchment.We analyzed socio-demographic and clinical data from a cohort of patients who were treated in a specialized early intervention service and who were at risk of relapse during a 3-year follow-up. Univariate analyses, logisti…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentYoung AdultCatchment Area HealthPredictive Value of TestsInternal medicineEpidemiologySecondary PreventionmedicineHumansLongitudinal StudiesFamily historyPsychiatryBiological PsychiatryProportional Hazards ModelsRetrospective StudiesPsychiatric Status Rating ScalesFirst episodeUnivariate analysisProportional hazards modelHazard ratioRetrospective cohort studyMiddle AgedSurvival AnalysisPsychiatry and Mental healthLogistic ModelsPsychotic DisordersCohortFemalePsychologyAntipsychotic AgentsJournal of Psychiatric Research
researchProduct

Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

2010

To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions.Two hundred and eighty inpatients with schizophrenia (DSM-IV criteria) were assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge.The mean duration of in…

AdultMalemedicine.medical_specialtyTime FactorsAntipsychotic treatmentSeverity of Illness IndexYoung Adult03 medical and health sciences0302 clinical medicineNaturalistic observationInternal medicineOutcome Assessment Health CareSeverity of illnessmedicineHumansYoung adultPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleRetrospective cohort studyMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaTime courseSchizophreniaRegression AnalysisFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia Research
researchProduct

Motherhood and Early Interaction in a Schizoaffective Patient: The Story of a Long-Term Psychotherapy

2010

This paper focused on motherhood in a patient with a schizoaffective disorder. The core of the treatment was to build a strong therapeutic alliance in which compliance with medication and elaboration of mental processes could be achieved. Pregnancy and motherhood are a time of crisis in the life of women. For the schizoaffective patient this crisis threatens the deepest level of functioning and challenges attachment patterns. Comprehensive treatment including psychosocial support, medication and psychotherapy is able to protect the baby to be, the early relationship between mother and baby, and the development of the child over time in this high-risk family. However, the commitment over yea…

AdultMalemedicine.medical_specialtyTime FactorsPsychotherapistMothersSchizoaffective disorderCompliance (psychology)Child DevelopmentLong term psychotherapyPregnancymedicineHumansChildPsychiatryPregnancyInfantLevel of functioningGeneral Medicinemedicine.diseaseObject AttachmentChild developmentMother-Child RelationsSocial relationPsychotherapyClinical PsychologyAlliancePsychotic DisordersChild PreschoolFemalePsychologyAmerican Journal of Psychotherapy
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care

2017

Medication non adherence in schizophrenia is a major cause of relapse and hospitalization and remains for clinicians an important challenge. This study investigates the associations between insight, therapeutic alliance, perceived trauma related to psychiatric treatment and medication adherence in patients with schizophrenia. In this multicenter study, 72 patients were assessed regarding symptomatology, self-reported adherence with medication, insight, medication side-effects, therapeutic alliance and perceived trauma related to psychiatric treatment. Structural Equation Modeling (SEM) was used to test predicted paths among these variables. The data fit a model in which medication adherence…

AdultMalemedicine.medical_specialty[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyMedication adherencePsychological TraumaStructural equation modelingMedication Adherence[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior03 medical and health sciences[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences0302 clinical medicineMedicineHumansIn patientPsychiatryBiological PsychiatryComputingMilieux_MISCELLANEOUS[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behaviorbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesProfessional-Patient RelationsAwarenessMiddle Agedmedicine.diseaseMental healthNon adherence030227 psychiatry3. Good healthPsychiatry and Mental healthAllianceMulticenter studySchizophrenia[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology[ SCCO.NEUR ] Cognitive science/NeuroscienceSchizophreniaFemalebusiness030217 neurology & neurosurgeryClinical psychologyAntipsychotic Agents
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach

1992

In vitro receptor-binding profiles and in vivo pharmacological studies have shown risperidone to be a potent mixed serotonin-S2 dopamine-D2-like receptor antagonist. While anti-D2 activity may relate to the antipsychotic potency of neuroleptic drugs, an antidepressive efficacy of substances with anti-S2 activity has been suggested. In an open pilot-study, ten patients with schizodepressive disorders or a DSM-III-R diagnosis of psychotic major depressive episodes were treated with risperidone (2-10 mg/d) for six weeks. Weekly psychopathological evaluation was performed, including BPRS, SANS, SAPS, VAS scales, and AIMS and UKU for the assessment of side-effects. Generally, the psychotic syndr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPiperidinesInternal medicineHumansMedicinePotencyPharmacology (medical)AntipsychoticDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderRisperidonebusiness.industryDopamine antagonistIsoxazolesSyndromeGeneral MedicineMiddle AgedRisperidoneReceptor antagonistBiperidenPsychiatry and Mental healthPsychotic DisordersAnesthesiaFemalebusinessAntipsychotic AgentsPsychopathologymedicine.drugPharmacopsychiatry
researchProduct

Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.

2011

Abstract Background To examine the influencing factors and predictors of early improvement in schizophrenia patients. Methods 370 patients suffering from a schizophrenia spectrum disorder were examined within a naturalistic multicenter study. Early improvement was defined as a ≥30% PANSS total score reduction within the first two treatment weeks, response as a ≥50% improvement of the PANSS total score from admission to discharge and remission according to the consensus remission criteria. Baseline and course-related variables such as positive, negative and depressive symptoms, side effects, functioning and subjective well-being were examined regarding their explanatory value for early impro…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMedizinAntipsychotic treatment03 medical and health sciencesYoung Adult0302 clinical medicineRemission criteriaPredictive Value of TestsInternal medicinemedicineHumansPsychiatryAntipsychoticBiological PsychiatryDepressive symptomsRetrospective StudiesPsychiatric Status Rating Scalesbusiness.industryMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthTreatment OutcomeMulticenter studyROC CurveSchizophreniaSchizophreniaFemalebusiness030217 neurology & neurosurgerySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesJournal of psychiatric research
researchProduct

Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum

2004

Mirtazapine is a novel antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. Because very little is known about serum concentrations in relation to clinical effects, the use of therapeutic drug monitoring is so far unclear. A rapid automated HPLC method with fluorescence detection was developed for routine quantification of mirtazapine and its demethylated metabolite N-desmethylmirtazapine in human serum. The precision of the method was suitable because the day-to-day (n = 7) coefficient of variation (CV) of mirtazapine was 9.8, 4.2, and 5.1% for concentrations of 10, 40, and 80 ng/mL, respectively, and the CV for N-desmethylmirtazapine were 11.6, 10.3, and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMetaboliteCoefficient of variationMirtazapineMirtazapineMianserinPharmacologySensitivity and Specificitychemistry.chemical_compoundInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticChromatography High Pressure LiquidAgedPharmacologySertralinemedicine.diagnostic_testbusiness.industryMiddle AgedEndocrinologychemistryTherapeutic drug monitoringHistamine H1 AntagonistsAntidepressantFemaleDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

Sauna Bathing and Risk of Psychotic Disorders : A Prospective Cohort Study

2018

<b><i>Objective:</i></b> Sauna bathing has been suggested to promote mental well-being and relaxation, but the evidence is uncertain with respect to mental disorders. We aimed to assess the association of frequency of sauna bathing with risk of psychosis in the Kuopio Ischemic Heart Disease prospective population-based study. <b><i>Subjects and Methods:</i></b> Baseline sauna bathing habits were assessed in 2,138 men aged 42–61 years who had no history of psychotic disorders. Participants were classified into three groups based on the frequency of sauna bathing (once, 2–3, and 4–7 times per week). <b><i>Results:</i></b>…

AdultMalemedicine.medical_specialtysaunasaunominenPopulationSteam Bath03 medical and health sciences0302 clinical medicinemielenterveysRisk FactorsInternal medicineSurveys and Questionnairesterveysvaikutuksetmedicinecohort studyHumansProspective StudiespsychosisRisk factorProspective cohort studyeducationkohorttitutkimusFinlandProportional Hazards Modelseducation.field_of_studyOriginal PaperProportional hazards modelbusiness.industrypsykoositConfoundingHazard ratioGeneral Medicineta3142riskitekijätMiddle AgedConfidence interval030227 psychiatryPsychotic Disordersrisk factorbusiness030217 neurology & neurosurgerymental healthCohort studyMedical Principles and Practice
researchProduct